InflaRx NV
IFRX1.270USD
-0.110-7.97%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
86.04MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über InflaRx NV Unternehmen
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV Informationen
BörsenkürzelIFRX
Name des UnternehmensInflaRx NV
IPO-datumNov 08, 2017
CEOProf. Niels C. Riedemann, M.D., Ph.D
Anzahl der mitarbeiter74
WertpapierartOrdinary Share
GeschäftsjahresendeNov 08
AddresseWinzerlaer Str. 2
StadtJENA
BörseNASDAQ Global Select Consolidated
LandGermany
Postleitzahl07745
Telefon493641508180
Websitehttps://www.inflarx.de/
BörsenkürzelIFRX
IPO-datumNov 08, 2017
CEOProf. Niels C. Riedemann, M.D., Ph.D
Führungskräfte von InflaRx NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Wed, Mar 5
Währung: USDAktualisiert: Wed, Mar 5
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Germany
0.00
0.00%
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Oct 28
Aktualisiert: Tue, Oct 28
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
9.57%
683 Capital Management LLC
3.65%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
Eversept Partners, LP
2.42%
Andere
78.84%
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
9.57%
683 Capital Management LLC
3.65%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
Eversept Partners, LP
2.42%
Andere
78.84%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
18.89%
Individual Investor
6.38%
Venture Capital
2.91%
Research Firm
1.48%
Investment Advisor
0.73%
Investment Advisor/Hedge Fund
0.52%
Bank and Trust
0.02%
Andere
69.08%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
77
16.71M
24.67%
-5.41M
2025Q2
85
22.06M
37.46%
-406.65K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
2023Q2
95
25.76M
47.58%
+2.86M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Suvretta Capital Management, LLC
6.48M
9.57%
--
--
Jun 30, 2025
683 Capital Management LLC
2.48M
3.65%
-150.00K
-5.71%
Jun 30, 2025
RA Capital Management, LP
1.97M
2.91%
+1.97M
--
Jun 30, 2025
Guo (Renfeng M.D.)
1.76M
2.6%
--
--
Dec 31, 2024
Eversept Partners, LP
1.64M
2.42%
-35.55K
-2.12%
Jun 30, 2025
Riedemann (Niels C. M.D.)
1.07M
1.58%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.42%
--
--
Dec 31, 2024
Woodline Partners LP
751.27K
1.11%
+283.00
+0.04%
Jun 30, 2025
Ikarian Capital LLC
705.01K
1.04%
+705.01K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
693.35K
1.02%
-567.80K
-45.02%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
